Prøve GULL - Gratis
TELANGANA WAGES WAR AGAINST COUNTERFEIT DRUGS
Bio Spectrum
|BioSpectrum India Oct 2024
Telangana contributes nearly one-third to India’s production and one-fifth to its exports in the pharmaceutical sector.

Hyderabad is a home to 800 pharma companies and life sciences capital of the country. To make the state free of spurious drugs, the Drugs Control Administration (DCA), Telangana is working relentlessly to detect spurious drugs movement in the market. In 2023 the DCA has carried out 26,133 inspections and taken action in 4984 cases with 4991 cases of violations. In the first four months of this year till April 2024 DCA has carried out 8495 inspections and found out that 50 drugs are ‘Not of Standard Quality’ (NSQ). Let’s look at how DCA is continuing its crusade against the spurious drugs issue and keep the public health of the state in order.
From the beginning of 2024, the DCA of Telangana, under the leadership of Director General (DG) V B Kamalasan Reddy, (who took charge as DG in July 2023) has intensified its efforts to combat the menace of spurious, fake and NSQ in the state. In the past few months, the DCA has targeted nearly 100 facilities across the state, resulting in the confiscation of 4000 to 5000 kgs of counterfeit medications worth Rs 50-60 crore. These recent raids have uncovered a widespread network of spurious drugs, highlighting the ongoing battle against counterfeit medications that pose a severe threat to public health.
Highlighting the efforts taken by the DCA of Telangana, Kamalasan Reddy said that he is committed to ensuring that quality, efficacy, and safety of medicines being supplied to the people in the state. “As part of this objective, we at the DCA have set our goals and accordingly devised plans for inspecting pharmaceutical companies, medical shops, medical device manufacturing companies, and blood banks across the state,” said Kamalasan Reddy.
Emerging pharmaceutical hub
Denne historien er fra BioSpectrum India Oct 2024-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Listen
Translate
Change font size